{
    "clinical_study": {
        "@rank": "121169", 
        "arm_group": [
            {
                "arm_group_label": "PRX002", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This single ascending dose study is to determine safety, tolerability, pharmacokinetics and\n      immunogenicity of PRX002 in approximately 40 healthy subjects."
        }, 
        "brief_title": "Single Ascending Dose Study of PRX002 in Healthy Subjects", 
        "condition": "Parkinson's Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy subjects\n\n          -  Body mass index (BMI) between 18-32 kg/m2 with a minimum weight of 46 kg\n\n          -  Female subjects must be surgically sterile or post-menopausal or if of child-bearing\n             potential must use contraception\n\n          -  Male subjects and their partners of childbearing potential must use contraception\n\n        Exclusion Criteria:\n\n          -  Positive test for drug of abuse\n\n          -  Past or current history of alcohol abuse\n\n          -  Positive for hepatitis B, hepatitis C or HIV infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02095171", 
            "org_study_id": "PRX002-CL001"
        }, 
        "intervention": [
            {
                "arm_group_label": "PRX002", 
                "intervention_name": "PRX002", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Antonio", 
                    "country": "United States", 
                    "state": "Texas"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of PRX002 Administered by Intravenous Infusion in Healthy Subjects", 
        "overall_contact": {
            "email": "theresa.neumann@prothena.com", 
            "last_name": "Theresa Neumann, PhD", 
            "phone": "(650) 615-2128"
        }, 
        "overall_official": {
            "affiliation": "Clinical Trials Neotope Biosciences Limited", 
            "last_name": "Theresa Neumann, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety and tolerability as determined by number of subjects with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 months"
            }, 
            {
                "description": "- maximum concentration (Cmax)", 
                "measure": "Determination of pharmacokinetics parameters", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 months"
            }, 
            {
                "description": "- time of the maximum measured concentration (Tmax)", 
                "measure": "Determination of pharmacokinetics parameters", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 months"
            }, 
            {
                "description": "- area under the concentration-time curve from time zero to the last quantifiable concentration time-point (AUClast)", 
                "measure": "Determination of pharmacokinetics parameters", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 months"
            }, 
            {
                "description": "- area under the concentration-time curve from time zero extrapolated to infinity (AUCinf)", 
                "measure": "Determination of pharmacokinetics parameters", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 months"
            }, 
            {
                "description": "- elimination rate constant", 
                "measure": "Determination of pharmacokinetics parameters", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 months"
            }, 
            {
                "description": "- terminal elimination half life (t\u00bd)", 
                "measure": "Determination of pharmacokinetics parameters", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 months"
            }, 
            {
                "description": "- clearance (CL)", 
                "measure": "Determination of pharmacokinetics parameters", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 months"
            }, 
            {
                "description": "- apparent volume of distribution (Vd)", 
                "measure": "Determination of pharmacokinetics parameters", 
                "safety_issue": "Yes", 
                "time_frame": "up to 3 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02095171"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Immunogenicity as determined by measurement of anti-PRX002 antibodies", 
            "safety_issue": "Yes", 
            "time_frame": "up to 3 months"
        }, 
        "source": "Neotope Biosciences Limited", 
        "sponsors": {
            "collaborator": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Neotope Biosciences Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}